Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBER salvage treatment followed by ibrutinib maintenance in transplant-ineligible relapsed/refractory PCNSL
KCT0004518Phase 2Completed
- Sponsor
- Chonnam National University Hwasun Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Chonnam National University Hwasun Hospital. Started Feb 2020; status: completed.
02
Drugs
ibrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on KCT0004518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004518.